Vutrisiran Wins Fast Track Designation for Polyneuropathy in hATTR Amyloidosis

Alnylam Pharmaceuticals recently completed enrollment in the phase 3 HELIOS-A clinical trial of the drug.

from Front page feed https://ift.tt/2Yl3Vx0